
    
      The primary objective of the open-label extension phase was the long-term assessment of
      safety and tolerability of Extended Release (ER) OROS paliperidone (3 mg to 12 mg/day) in
      subjects (>65 years of age) with schizophrenia, and the secondary objective was the
      assessment of long-term efficacy.

      Paliperidone ER OROSÂ® tablet formulation (3 to 12 mg/day) to be taken orally
    
  